Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals - PubMed

Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals

D M O'Gorman et al. Leukemia. 2000 Apr.

Abstract

Drug resistance remains a serious limiting factor in the treatment of acute myeloid leukaemia (AML) either at initial presentation or following primary or subsequent relapses. Using specific kinase inhibitors, this study has investigated the contribution of the Ras/PI3-kinase regulated survival pathways to drug resistance and suppression of apoptosis in a cell line derived from AML (HL60). Inhibition of the Raf/MAP-kinase (ERK) pathway with a specific MAP-kinase inhibitor, apigenin did not sensitise HL60 cells to drug-induced apoptosis, indicating a lack of involvement in chemoresistance. In contrast, the PI3-kinase inhibitors, LY294002 and wortmannin, did induce a significant increase in apoptosis in combination with cytotoxic drugs. The contribution of downstream mediators of PI3-kinase, p70S6-kinase and PKB/Akt were then investigated. While inhibition of p70S6-kinase with rapamycin did not increase drug-induced apoptosis, PI3-kinase inhibition resulted in notable dephosphorylation of PKB, suggesting that the PI3-kinase/PKB survival pathway may play a major role in chemoresistance in AML. This pathway has been reported to mediate heterodimer interactions with the proapoptotic regulator, Bad. In contrast to previous studies, we found no evidence of Bad binding to anti-apoptotic Bcl-2, Bcl-XL or McI-1, or of alterations in Bax heterodimers. This suggests that alternative targets of PI3-kinase/PKB, distinct from the Bcl-2 family may be responsible for contributing to survival factor-mediated drug resistance in AML.

Similar articles

• A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.

  Martelli AM, Tazzari PL, Tabellini G, Bortul R, Billi AM, Manzoli L, Ruggeri A, Conte R, Cocco L. Martelli AM, et al. Leukemia. 2003 Sep;17(9):1794-805. doi: 10.1038/sj.leu.2403044. Leukemia. 2003. PMID: 12970779

• The PI3-kinase-Akt pathway promotes mesangial cell survival and inhibits apoptosis in vitro via NF-kappa B and Bad.

  Shimamura H, Terada Y, Okado T, Tanaka H, Inoshita S, Sasaki S. Shimamura H, et al. J Am Soc Nephrol. 2003 Jun;14(6):1427-34. doi: 10.1097/01.asn.0000066140.99610.32. J Am Soc Nephrol. 2003. PMID: 12761242

• Activation of PI3-kinase/PKB contributes to delay in neutrophil apoptosis after thermal injury.

  Hu Z, Sayeed MM. Hu Z, et al. Am J Physiol Cell Physiol. 2005 May;288(5):C1171-8. doi: 10.1152/ajpcell.00312.2004. Epub 2004 Dec 29. Am J Physiol Cell Physiol. 2005. PMID: 15625305

• Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance.

  Deng X, Kornblau SM, Ruvolo PP, May WS Jr. Deng X, et al. J Natl Cancer Inst Monogr. 2001;(28):30-7. doi: 10.1093/oxfordjournals.jncimonographs.a024254. J Natl Cancer Inst Monogr. 2001. PMID: 11158204 Review.

• Role of the C5b-9 complement complex in cell cycle and apoptosis.

  Rus HG, Niculescu FI, Shin ML. Rus HG, et al. Immunol Rev. 2001 Apr;180:49-55. doi: 10.1034/j.1600-065x.2001.1800104.x. Immunol Rev. 2001. PMID: 11414362 Review.

Cited by

• Differentiation, apoptosis, and function of human immature and mature myeloid cells: intracellular signaling mechanism.

  Yuo A. Yuo A. Int J Hematol. 2001 Jun;73(4):438-452. doi: 10.1007/BF02994005. Int J Hematol. 2001. PMID: 11503957 Review.

• Vanillins--a novel family of DNA-PK inhibitors.

  Durant S, Karran P. Durant S, et al. Nucleic Acids Res. 2003 Oct 1;31(19):5501-12. doi: 10.1093/nar/gkg753. Nucleic Acids Res. 2003. PMID: 14500812 Free PMC article.

• Bcl-2 and apoptosis in chronic lymphocytic leukemia.

  Schimmer AD, Munk-Pedersen I, Minden MD, Reed JC. Schimmer AD, et al. Curr Treat Options Oncol. 2003 Jun;4(3):211-8. doi: 10.1007/s11864-003-0022-y. Curr Treat Options Oncol. 2003. PMID: 12718798 Review.

• Novel postremission strategies in adults with acute myeloid leukemia.

  Lancet JE, Karp JE. Lancet JE, et al. Curr Opin Hematol. 2009 Mar;16(2):105-11. doi: 10.1097/MOH.0b013e3283257b04. Curr Opin Hematol. 2009. PMID: 19468272 Free PMC article. Review.

• Mapping genes that contribute to daunorubicin-induced cytotoxicity.

  Duan S, Bleibel WK, Huang RS, Shukla SJ, Wu X, Badner JA, Dolan ME. Duan S, et al. Cancer Res. 2007 Jun 1;67(11):5425-33. doi: 10.1158/0008-5472.CAN-06-4431. Cancer Res. 2007. PMID: 17545624 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal